Accurate Determination of Tartrate in Drug Products in Just 10 Minutes
The Application Notebook
Thermo Scientific
Tolterodine, a quaternary ammonium compound, is used to treat urinary incontinence. To create the drug substance, tolterodine is paired with tartrate to form tolterodine tartrate. This drug substance can then be used to create drug products. One way to confirm the amount of a drug substance in a drug product is to assay for its counterion. This is especially true for counterions such as tartrate that are unlikely to originate from any other sample components. Ion chromatography (IC) with suppressed conductivity detection is a common technique for counterion determinations. Here we report an IC method to determine tartrate in a tolterodine tartrate drug product that is faster, requires less labour and eliminates analyst exposure to strong acid relative to a recently published IC method (1).
Equipment
A Thermo Scientific Dionex ICS-5000 IC System configured with an EG Eluent Generator module, DC Detector/Chromatography Compartment and CD Conductivity Detector was used. Samples were introduced by an AS-AP Autosampler. All data collection and processing was controlled by Thermo Scientific Dionex Chromeleon Chromatography Data System software. Complete experimental details are found in reference 2.
Results
Figure 1 Trace A shows the determination of tartrate in a capsule drug product containing tolterodine tartrate. Tartrate is resolved from other anions in the sample using a Thermo Scientific Dionex IonPac AS20 Hydroxide-Selective Anion-Exchange Column set with 20 mM potassium hydroxide. The eluent is produced by the eluent generator, and therefore the labor and possible error associated with eluent preparation are eliminated. Tartrate is detected by suppressed conductivity in the recycle mode, indicating that the analyst does not have to prepare a strong acid solution for suppressed conductivity detection. Figure 1 Trace B shows the same sample to which an additional 4 mg/L tartrate was added. For a set of five samples there was 100% recovery of the added tartrate. The same unfortified five samples had 98.4% of the labeled amount of drug substance as measured by tartrate concentration. Both results indicate good method accuracy. Overall this is an accurate IC method for determining tartrate that does not require the analyst to prepare eluent or strong acid regenerant.
Figure 1: Determination of tartrate in a drug capsule: Trace A shows the sample and Trace B is the sample to which 4 mg/L tartrate was added before sample preparation.
References
(1) G.R. Deshpande, B.M. Rao, and N. Someswararao, "Quantitative Determination of Tartaric Acid in Tolterodine Tartrate by Ion Chromatography Using Conductivity Detection," RASAYAN J. Chem., 2101–2107 (2009).
(2) Thermo Scientific Application Note 1002: Determination of Tartaric Acid in Tolterodine Tartrate Drug Products by IC with Suppressed Conductivity Detection, Sunnyvale, California, USA, 2012. [Online] http://www.dionex.com/en-us/webdocs/113488-AN1002-IC-TartaricAcid-TolterodineTartrate-02May2012-LPN3065.pdf (accessed May 31, 2012).
Receive the complete application note at: www.thermoscientific/AN1002
Thermo Fisher Scientific Inc.
1228 Titan Way, P.O. Box 3603, Sunnyvale, California 94088-3603, USA
tel. (800) 532 4752
Website: www.thermoscientific.com/dionex
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
